Travel-associated cutaneous larva migrans: Clinical recognition and management of an imported case in Albania.

Parasitol IntApr 9, 2026 (epub)
Case ReportDermatologyInfectious Diseases

Edmond Puca, Entela Puca, Irena Savo et al.

✦ AI-curated · Sources linked

Case in brief

A female traveller presented in Albania with an itchy, winding skin lesion on her foot after exposure to river water during a visit to Oman. The lesion’s characteristic serpiginous appearance, together with her travel history, supported a clinical diagnosis of cutaneous larva migrans. She responded completely to a short course of albendazole.

What made this case unusual

The case was identified in Albania, where the authors report that no dermatologic lesion diagnosed as cutaneous larva migrans had previously been reported.

Diagnostic / clinical pearl

In a returning traveller, a pruritic, serpiginous skin lesion and relevant exposure history can support clinical recognition of cutaneous larva migrans.

Source

PubMed · PMID 41966475

Published in Parasitol Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.